As the IP community waits for movement on the Biden Administration’s proposal to expand the scope of the march-in rights provision under the Bayh-Dole Act, the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) has been actively countering the administration’s argument that such a mechanism would effectively lower drug prices. The comment period for the National Institute of Standards & Technology (NIST) and the Department of Commerce’s Request for Information (RFI) on the proposal closed in early February. Since then, it has been rumored several times that the framework would be finalized and published, but those rumors never materialized.
Recent Posts
- SoftView Petitions Full Federal Circuit to Rehear Decision on Patentee Estoppel at USPTO
- Other Barks & Bites for Friday, August 30: WIPO Publishes Top Technology Cluster List; Romania Joins Unitary Patent System; TikTok Trend Sparks Trademark Controversy
- CAFC Affirms Most of PTAB Ruling Invalidating Philips’ Radio Communication System Patent Claims
- CAFC Nixes New Trial for WARF Against Apple on Doctrine-of-Equivalents Theory
- March-In Impact, Advice from In-House, and More on Day Two of IPWatchdog’s Women’s IP Forum